Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 172, Issue 5, 2015, Pages 627-638

  Glintborg, Dorte ^a   Rubin, Katrine Hass ^b   Nybo, Mads ^a   Abrahamsen, Bo ^b   Andersen, Marianne ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DEPRESSION; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FEMALE INFERTILITY; FRACTURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MIGRAINE; MORBIDITY; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PREMENOPAUSE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; THYROID DISEASE; BLOOD; BODY MASS; COMPLICATION; MENSTRUAL CYCLE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; REGISTER; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

INSULIN; TESTOSTERONE;

ADOLESCENT; ADULT; BODY MASS INDEX; CHILD; DENMARK; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INSULIN; MENSTRUAL CYCLE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; PREMENOPAUSE; PREVALENCE; REGISTRIES; TESTOSTERONE; YOUNG ADULT;

EID: 84929515061     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-1108     Document Type: Article

References (52)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19-25. (doi:10.1016/j.fertnstert.2003.10.004)
2. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. European Journal Endocrinology 2014 4 1-29. (doi:10.1530/EJE-14-0253)
3. Glintborg D & Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecological Endocrinology 2010 4 281-296. (doi:10.3109/ 09513590903247873)
4. Azziz R. The evaluation and management of hirsutism. Obstetrics and Gynecology 2003 5 995-1007. (doi:10.1016/S0029-7844(02)02725-4)
5. Moghetti P, Tosi F, Bonin C, Di SD, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, DalleAlda M et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2013 4 E628-E637. (doi:10.1210/jc.2012-3908)
6. OeReilly MW, Taylor AE, Crabtree NJ, Hughes BA, Capper F, Crowley RK, Stewart PM, Tomlinson JW& Arlt W. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. Journal of Clinical Endocrinology and Metabolism 2014 99 1027-1036.
7. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK & Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999 1 141-146. (doi:10.2337/diacare.22.1.141)
8. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen PE, Schousboe K & Hermann AP. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertility and Sterility 2004 6 1570-1579. (doi:10.1016/j.fertnstert.2004.06.040)
9. Tomlinson J, Millward A, Stenhouse E & Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabetic Medicine 2010 5 498-515. (doi:10.1111/j.1464-5491.2010.02994.x)
10. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH & Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology 1998 7 581-586. (doi:10.1016/S0895-4356(98)00035-3)
11. Wild S, Pierpoint T, McKeigue P & Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clinical Endocrinology 2000 5 595-600. (doi:10.1046/j.1365-2265.2000.01000.x)
12. Dahlgren E, Janson PO, Johansson S, Lapidus L & Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstetricia et Gynecologica Scandinavica 1992 8 599-604. (doi:10.3109/00016349209006227)
13. Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, Blackledge H, Khunti K & Howlett TA. Diabetes and cardiovascular events in women with polycystic ovary syndrome: A 20-year retrospective cohort study. Clinical Endocrinology 2013 6 926-934. (doi:10.1111/cen.12068)
14. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A position statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 5 2038-2049. (doi:10.1210/jc.2009-2724)
15. Hefler-Frischmuth K,Walch K, Huebl W, Baumuehlner K, Tempfer C & Hefler L. Serologic markers of autoimmunity in women with polycystic ovary syndrome. Fertility and Sterility 2010 7 2291-2294. (doi:10.1016/j. fertnstert.2009.01.056)
16. Al-Saab R & Haddad S. Detection of thyroid autoimmunity markers in euthyroid women with polycystic ovary syndrome: A case-control study from Syria. International Journal of Endocrinology and Metabolism 2014 3 e17954.
17. Macsali F, Svanes C, Bjorge L, Omenaas ER & Gomez RF. Respiratory health in women: from menarche to menopause. Expert Review of Respiratory Medicine 2012 2 187-200. (doi:10.1586/ers.12.15)
18. Cinar N, Kizilarslanoglu MC, Harmanci A, Aksoy DY, Bozdag G, Demir B & Yildiz BO. Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Human Reproduction 2011 12 3339-3345. (doi:10.1093/humrep/der338)
19. Jones GL, Hall JM, Balen AH & Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: A systematic review. Human Reproduction Update 2008 1 15-25.
20. Altinok ML, Glintborg D, Depont CR, Hallas J & Andersen M. Prescription of antidepressants is increased in Danish patients with polycystic ovary syndrome and is associated with hyperandrogenism. A population-based cohort study. Clinical Endocrinology 2013 80 884-889. (doi:10.1111/cen.12365)
21. Azziz R, Sanchez LA, Knochenhauer ES,MoranC, Lazenby J, StephensKC, Taylor K & Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. Journal of Clinical Endocrinology andMetabolism 2004 2 453-462. (doi:10.1210/jc.2003-031122)
22. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF et al. Epidemiology, diagnosis and management of hirsutism: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update 2012 2 146-170. (doi:10.1093/humupd/dmr042)
23. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism 2006 11 4237-4245. (doi:10.1210/jc.2006-0178)
24. Ferriman D & Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology 1961 21 1440-1447. (doi:10.1210/jcem-21-11-1440)
25. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S & Svenstrup B. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clinical Endocrinology 1985 4 385-393. (doi:10.1111/j.1365-2265. 1985.tb01096.x)
26. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. Journal of Clinical Endocrinology and Metabolism 2000 12 4426-4433.
27. Lynge E, Sandegaard JL & Rebolj M. The Danish National Patient Register. Scandinavian Journal of Public Health 2011 39 (7 Suppl) 30-33. (doi:10.1177/1403494811401482)
28. Nader S. Hyperandrogenism during puberty in the development of polycystic ovary syndrome. Fertility and Sterility 2013 1 39-42. (doi:10.1016/j.fertnstert.2013.03.013)
29. Forman MR, Mangini LD, Thelus-Jean R & Hayward MD. Life-course origins of the ages at menarche and menopause. Adolescent Health, Medicine and Therapeutics 2013 4 1-21. (doi:10.2147/AHMT.S15946)
30. Charlson ME, Pompei P, Ales KL & MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987 5 373-383. (doi:10.1016/0021-9681(87)90171-8)
31. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE & Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005 11 1130-1139. (doi:10.1097/01.mlr.0000182534. 19832.83)
32. Morgan CL, Jenkins-Jones S, Currie CJ & Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: A retrospective, observational study. Journal of Clinical Endocrinology and Metabolism 2012 9 3251-3260. (doi:10.1210/jc.2012-1690)
33. Bajuk SK, Jensterle SM & Pfeifer M. Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome. Frontiers of Hormone Research 2013 40 64-82. (doi:10.1159/000341838)
34. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L & Pasquali R. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 2012 9 2369-2374. (doi:10.2337/db11-1360)
35. Glintborg D, Mumm H, Hougaard D, Ravn P & Andersen M. Ethnic differences in Rotterdam criteria and metabolic risk factors in a multiethnic group of women with PCOS studied in Denmark. Clinical Endocrinology 2010 6 732-738. (doi:10.1111/j.1365-2265.2010.03873.x)
36. Bird ST, Hartzema AG, Brophy JM, Etminan M & Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: A population-based matched cohort analysis. CMAJ: Canadian Medical Association Journal 2013 2 E115-E120. (doi:10.1503/cmaj.120677)
37. Gronich N, Lavi I & Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: A population-based cohort study. CMAJ: Canadian Medical Association Journal 2011 18 E1319-E1325. (doi:10.1503/cmaj.110463)
38. Novais JD, Benetti-Pinto CL, Garmes HM, Menezes JR & Juliato CR. Polycystic ovary syndrome and chronic autoimmune thyroiditis. Gynecological Endocrinology 2014 31 1-4. (doi:10.3109/09513590.2014. 958990)
39. Hung JH, Hu LY, Tsai SJ, Yang AC, Huang MW, Chen PM, Wang SL, Lu T & Shen CC. Risk of psychiatric disorders following polycystic ovary syndrome: A nationwide population-based cohort study. PLoS ONE 2014 5 e97041. (doi:10.1371/journal.pone.0097041)
40. Glaser R, Dimitrakakis C, Trimble N & Martin V. Testosterone pellet implants and migraine headaches: A pilot study. Maturitas 2012 4 385-388. (doi:10.1016/j.maturitas.2012.01.006)
41. Check JH & Cohen R. Dihydrotestosterone may contribute to the development of migraine headaches. Clinical and Experimental Obstetrics & Gynecology 2013 2 217-218.
42. Glintborg D, Hermann A & Andersen M. Bone mineral density and vitamin D in PCOS and hirsutism. Expert Review of Endocrinology & Metabolism 2013 5 449-459. (doi:10.1586/17446651.2013.827384)
43. Gregoriou O, Kouskouni E, Bakas P, Konidaris S, Papadias K, Kalovidouris A & Creatsas G. Bone mineral density in women with idiopathic hirsutism. Gynecological Endocrinology 2000 5 364-368. (doi:10.3109/09513590009167704)
44. Reid IR, Plank LD & Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. Journal of Clinical Endocrinology and Metabolism 1992 3 779-782. (doi:10.1210/jcem.75.3.1517366)
45. Abrahamsen B, Rohold A, Henriksen JE & Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabetic Medicine 2000 2 124-129. (doi:10.1046/j.1464-5491. 2000.00234.x)
46. Glintborg D, Andersen M, Hagen C & Hermann AP. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clinical Endocrinology 2005 6 683-691. (doi:10.1111/j.1365-2265.2005.02280.x)
47. Thomson RL, Spedding S, Brinkworth GD, Noakes M & Buckley JD. Seasonal effects on vitamin D status influence outcomes of lifestyle intervention in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility 2013 6 1779-1785. (doi:10.1016/j. fertnstert.2012.12.042)
48. Schmidt J, Dahlgren E, Brannstrom M & Landin-Wilhelmsen K. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome-a long-term follow-up study. Clinical Endocrinology 2012 2 207-214. (doi:10.1111/j.1365-2265. 2012.04378.x)
49. Sirmans SM & Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology 2013 6 1-13. (doi:10.2147/CLEP.S37559)
50. De Frene V, Vansteelandt S, TeSjoen G, Gerris J, Somers S, Vercruysse L & De Sutter P. A retrospective study of the pregnancy, delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome. Human Reproduction 2014 10 2333-2338. (doi:10.1093/humrep/deu154)
51. Cussons AJ, Stuckey BG, Walsh JP, Burke V & Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical Endocrinology 2005 3 289-295. (doi:10.1111/j.1365-2265.2004.02208.x)
52. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2013 12 4565-4592. (doi:10.1210/ jc.2013-2350)